Jm. Bouchard et al., CITALOPRAM AND VILOXAZINE IN THE TREATMENT OF DEPRESSION BY MEANS OF SLOW DROP INFUSION - A DOUBLE-BLIND COMPARATIVE TRIAL, Journal of affective disorders, 46(1), 1997, pp. 51-58
Antidepressant efficacy and tolerability of citalopram and viloxazine
were compared under double-blind conditions during the first two weeks
of treatment with slow drop infusion, followed by oral administration
for the rest of the six week trial period. The 62 severely depressed
and hospitalised patients included in the intention-to-neat analysis h
ad a mean age of 45 years (range 23 to 70 years). About two thirds of
the patients were female. Thirty patients were allocated to the citalo
pram and 32 patients to the viloxazine group. The mean MADRS total sco
re at baseline was 34 in both groups and decreased to 12.3 in the cita
lopram and to 16.9 in the viloxazine group after 14 days of infusion.
On day 42 (end point) the scores dropped to 6.7 in the citalopram and
to 13.1 in the viloxazine group respectively. The group differences re
ached the level of significance at both time points (p < 0.05) in favo
ur of citalopram. The analysis of treatment emergent adverse events ba
sed on the UKU scale showed a higher frequency of nausea on day 14 and
constipation at study end in the viloxazine group (p < 0.05) whereas
reported weight gain (day 21) and concentration difficulty (day 21) we
re more frequently seen in the citalopram group (p < 0.05). Standard l
aboratory investigations and ECG analyses did not show clinically rele
vant abnormalities. It is concluded that antidepressant treatment with
citalopram infusion followed by oral citalopram may be more efficacio
us than a corresponding treatment schedule with viloxazine. (C) 1997 E
lsevier Science B.V.